Sibeprenlimab
Sibeprenlimab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target tumor necrosis factor ligand superfamily member 13.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Voyxact
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| voyxact | Biologic Licensing Application | 2025-11-30 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 2 | 2 | — | — | 3 |
| Iga glomerulonephritis | D005922 | EFO_0004194 | — | — | 2 | 2 | — | — | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Immune system diseases | D007154 | — | D89.9 | — | 1 | — | — | — | 1 |
| Dry eye syndromes | D015352 | — | H04.12 | — | 1 | — | — | — | 1 |
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | — | 1 | — | — | — | 1 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | 1 | — | — | — | 1 |
| Xerostomia | D014987 | — | K11.7 | — | 1 | — | — | — | 1 |
| Salivary gland diseases | D012466 | EFO_0008581 | K11 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sibeprenlimab |
| INN | sibeprenlimab |
| Description | Sibeprenlimab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target tumor necrosis factor ligand superfamily member 13. |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594614 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | GHX28QZ7DD (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
TNFSF13
TNFSF13
Organism
Homo sapiens
Gene name
TNFSF13
Gene synonyms
APRIL, TALL2, ZTNF2
NCBI Gene ID
Protein name
tumor necrosis factor ligand superfamily member 13
Protein synonyms
A proliferation-inducing ligand, APRIL, CD256, TALL-2, TNF- and APOL-related leukocyte expressed ligand 2, TNF-related death ligand 1, TRDL-1, tumor necrosis factor (ligand) superfamily, member 13, tumor necrosis factor ligand 7B, tumor necrosis factor superfamily member 13, tumor necrosis factor-like protein ZTNF2, tumor necrosis factor-related death ligand-1
Uniprot ID
Mouse ortholog
Tnfsf13 (69583)
tumor necrosis factor ligand superfamily member 13 (Q9ERP1)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 111 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use